![](https://www.ayanapharma.com/wp-content/uploads/2019/10/line002.png)
Technology
Liposomal Nano-pharmaceuticals
- Improved therapeutic index (increased efficacy & reduced toxicity) by:
- Passive targeted accumulation in diseased tissue
- Sparing healthy tissues / organs
- Protect API allowing controlled/sustained release at target
- Biocompatible, biodegradable, non immunogenic
- Scientifically well accepted nano delivery system
![](https://www.ayanapharma.com/wp-content/uploads/2019/10/img-005.jpg)
- FDA is increasingly accustomed to Liposomal drugs – growth in the submissions of drug products containing nanomaterials, largest class of products being Liposomal formulations intended for cancer treatments*
- Provides high entrance barriers for competition
- Liposomal nano technology is advantageous in many indications (e.g. cancer, inflammation, infection)
Ayana has core competence in development & manufacturing of complex Liposomal nano-drugs
* Nature Nanotechnology Analysis (published on-line April 17, 2017)